Zydus Lifesciences holds 31st AGM on August 11, 2026

1 min read | Published on 01 Sept 2026, 11:19 AM |Updated on 01 Sept 2026, 11:19 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Zydus Lifesciences held its 31st AGM via video conference on August 11, 2026
The meeting lasted from 10:00 am to 11:16 am IST
Chairman Pankaj R. Patel and MD Sharvil P. Patel attended
Statutory auditors from Deloitte Haskins & Sells LLP were present
Proceedings were recorded and posted on the company website

*this image is generated using AI for illustrative purposes only.

Zydus Lifesciences Limited conducted its 31st Annual General Meeting through video conferencing on Tuesday, August 11, 2026. The session ran from 10:00 am to 11:16 am IST.

The meeting adhered to the provisions of the Companies Act, 2013 and circulars issued by the Ministry of Corporate Affairs and SEBI. Dhaval N. Soni, Company Secretary and Compliance Officer, assisted Chairman Pankaj R. Patel in conducting the proceedings.

Key Attendees

Directors, key managerial personnel, and auditors attended the meeting via video conferencing or other audio-visual means. The following officials were present:

Name	Role
Pankaj R. Patel	Chairman
Sharvil P. Patel	Managing Director
Ganesh N. Nayak	Director
Bhadresh K. Shah	Independent Director
Shelina P. Parikh	Independent Woman Director
Akhil A Monappa	Independent Director
Kulin S. Lalbhai	Independent Director
Mukesh M. Patel	Non-Executive Director
Tushar D. Shroff	Chief Financial Officer
Dhaval N. Soni	Company Secretary
Kartikeya Raval	Partner-Deloitte Haskins & Sells LLP
Ashish Doshi	Secretarial Auditor

Procedural Details

Members remained in mute mode during the session to avoid background disturbance. Audio and video were enabled only for pre-registered speakers. The proceedings were recorded and made available on the company website.

The transcript is hosted at www.zyduSlife.com . Ashish Doshi served as the scrutinizer for remote e-voting and e-voting during the AGM.

Historical Stock Returns for Zydus Life Science

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.36%	+5.59%	+3.43%	+26.45%	+18.80%	+110.32%

What strategic growth initiatives or capital allocation plans did Chairman Pankaj R. Patel outline for Zydus Lifesciences in the upcoming fiscal year?

How might the company's performance metrics discussed at the AGM influence its valuation relative to other major Indian pharmaceutical peers?

Are there any pending regulatory approvals or clinical trial results for key pipeline drugs that management highlighted as critical near-term catalysts?

Zydus Life Science

View Company Insights

View All News

Zydus Lifesciences sets up treasury subsidiary in Gujarat IFSC

1 min read | Published on 26 Aug 2026, 12:28 PM |Updated on 26 Aug 2026, 12:28 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

Zydus Lifesciences incorporated ZyduS Global Treasury Centre IFSC Limited on August 25, 2026
The wholly owned subsidiary is based in Gift City, Gandhinagar, with ₹5 crore paid-up capital
The entity will manage global and regional corporate treasury activities and services
The parent company subscribed to 100% of the share capital in cash
The filing was made under SEBI Listing Regulations Regulation 30

*this image is generated using AI for illustrative purposes only.

Zydus Life Science incorporated a wholly owned subsidiary, ZyduS Global Treasury Centre IFSC Limited, on August 25, 2026. The entity is based in Gift City, Gandhinagar, Gujarat.

The company filed an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular dated January 30, 2026.

Subsidiary Details

The new entity aims to undertake business as a Global or Regional Corporate Treasury Centre. It will carry out treasury activities and treasury services for the group.

Particulars	Details
Entity Name	ZyduS Global Treasury Centre IFSC Limited
Authorized Capital	₹5 crore
Paid-up Capital	₹5 crore
Turnover	Nil
Shareholding	100% by Zydus Lifesciences

The parent company subscribed to the entire paid-up share capital in cash. Since the subsidiary is newly incorporated, it has not commenced business operations. Its turnover is currently nil.

Regulatory Compliance

Dhaval N. Soni, Company Secretary and Compliance Officer, signed the disclosure. The filing confirms that the incorporation does not constitute a related party transaction involving promoters or group companies at the time of formation. Upon incorporation, the subsidiary becomes a related party of the listed entity.

No governmental or regulatory approvals were required for this internal corporate action.

Historical Stock Returns for Zydus Life Science

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.36%	+5.59%	+3.43%	+26.45%	+18.80%	+110.32%

How is the establishment of the Global Treasury Centre in IFSC expected to impact Zydus Lifesciences' foreign exchange hedging costs and currency risk management?

What specific tax incentives or regulatory benefits from the Gujarat International Finance Tec-City (GIFT City) framework will this subsidiary leverage to enhance group profitability?

Will the centralization of treasury functions through this subsidiary lead to improved cash flow visibility and working capital efficiency for Zydus Lifesciences?

Zydus Life Science

View Company Insights

View All News